Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Craniopharyngioma × dabrafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 68 Neoplasms 25 Neoplasm Metastasis 11 Carcinoma, Non-Small-Cell Lung 10 Thyroid Carcinoma, Anaplastic 9 Thyroid Neoplasms 8 Glioma 8 Brain Neoplasms 8 Skin Neoplasms 6 Multiple Myeloma 6 Hematologic Neoplasms 5 Colorectal Neoplasms 4 Ameloblastoma 4 Thyroid Cancer, Papillary 3 Glioblastoma 3 Astrocytoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Oligodendroglioma 2 Neurocytoma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Histiocytosis, Langerhans-Cell 2 Ganglioneuroma 2 Ganglioglioma 2 Fever 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Thrombocytosis 1 Solid Tumor 1

Interventions

Surgical Procedures, Operative 3 Exenatide 3 tocilizumab 2 Temozolomide 2 Surveys and Questionnaires 2 Mental Status and Dementia Tests 2 Magnetic Resonance Spectroscopy 2 Donepezil 2 trametinib 1 tozuleristide 1 tovorafenib 1 temsirolimus 1 gallium Ga 68 dotatate 1 entinostat 1 dabrafenib 1 cobimetinib 1 carboxyamido-triazole 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 anlotinib 1 Verteporfin 1 Vemurafenib 1 Tumor Burden 1 Transurethral Resection of Bladder 1 Thalidomide 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Image-Guided 1 Radiotherapy, Conformal 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05525273 2024-02-14

Swecranio

Skane University Hospital

Phase 2 Recruiting

Craniopharyngioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡